Evidence map›Paper›PMID 26791201›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

Direct Transcriptional Effects of Apolipoprotein E.

Veena Theendakara, Clare A Peters-Libeu, Patricia Spilman, Karen S Poksay, Dale E Bredesen, Rammohan V Rao

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Veena TheendakaraBuck Institute for Research on Aging, Novato, California 94945, and.
Clare A Peters-LibeuBuck Institute for Research on Aging, Novato, California 94945, and.
Patricia SpilmanBuck Institute for Research on Aging, Novato, California 94945, and Easton Laboratories for Neurodegenerative Disease Research, University of California Los Angeles, Los Angeles, California 90025.ORCID http://orcid.org/0000-0003-1999-1169
Karen S PoksayBuck Institute for Research on Aging, Novato, California 94945, and.
Dale E BredesenBuck Institute for Research on Aging, Novato, California 94945, and Easton Laboratories for Neurodegenerative Disease Research, University of California Los Angeles, Los Angeles, California 90025 dbredesen@mednet.ucla.edu rrao@buckinstitute.org.
Rammohan V RaoBuck Institute for Research on Aging, Novato, California 94945, and dbredesen@mednet.ucla.edu rrao@buckinstitute.org.
Buck Institute for Research on Aging · US

Funding

Novel Prionic Mechanism Underlying Alzheimer?s DiseaseR01AG034427 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI BREDESEN, DALE E. · 2009 to 2012
$1.5M
NIA NIH HHS AG034427NIA NIH HHS R01 AG034427
6 · The paper itself

Abstract

A major unanswered question in biology and medicine is the mechanism by which the product of the apolipoprotein E ε4 allele, the lipid-binding protein apolipoprotein E4 (ApoE4), plays a pivotal role in processes as disparate as Alzheimer's disease (AD; in which it is the single most important genetic risk factor), atherosclerotic cardiovascular disease, Lewy body dementia, hominid evolution, and inflammation. Using a combination of neural cell lines, skin fibroblasts from AD patients, and ApoE targeted replacement mouse brains, we show in the present report that ApoE4 undergoes nuclear translocation, binds double-stranded DNA with high affinity (low nanomolar), and functions as a transcription factor. Using chromatin immunoprecipitation and high-throughput DNA sequencing, our results indicate that the ApoE4 DNA binding sites include ∼1700 gene promoter regions. The genes associated with these promoters provide new insight into the mechanism by which AD risk is conferred by ApoE4, because they include genes associated with trophic support, programmed cell death, microtubule disassembly, synaptic function, aging, and insulin resistance, all processes that have been implicated in AD pathogenesis. Significance statement: This study shows for the first time that apolipoprotein E4 binds DNA with high affinity and that its binding sites include 1700 promoter regions that include genes associated with neurotrophins, programmed cell death, synaptic function, sirtuins and aging, and insulin resistance, all processes that have been implicated in Alzheimer's disease pathogenesis.

Indexed as

AgedAnimalsApolipoprotein E4Base SequenceBrainCell Line, TumorFemaleFibroblastsHumansMaleMiceMice, KnockoutMice, TransgenicMiddle AgedMolecular Sequence DataNeuronsApolipoprotein E4activity-dependent neuroprotective proteinAlzheimer's diseaseamyloid precursor proteinapolipoprotein EMAP kinase-activating death domainsirtuin

Identifiers

PMID26791201
PMCPMC4719010
OpenAlexW2318325474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.